

January 14, 2010

D. Western Therapeutics Institute, Inc.  
1-18-11, Nishiki, Naka-ku, Nagoya-city, Aichi-pref. 460-0003 JAPAN

(translation)

### Notice regarding completion of compound optimization for new anti-glaucoma drug

D. Western Therapeutics Institute, Inc. (DWTI), announced that they have completed compound optimization phase for new anti-glaucoma drug from their development project on protein kinase inhibitors.

Glaucoma is a eye disease characterized by narrow field of vision due to damage of the optic nerve or retina and it result in progressive vision loss. The number of glaucoma patients is increasing as a result of growing population of aged people. Medications for glaucoma patients are usually effective at lowering intraocular pressure (IOP) and thus preventing optic nerve damage.

DWTI have pursued compound optimization by enhancing efficacy and safety suitable for a drug candidate since the last years. DWTI selected a final candidate of effective in vivo activity with safe property.

Now it is announced that the new anti-glaucoma drug is born with good safety profile and potent IOP lowering activity.

DWTI is going to elucidate mechanism of action of the candidate drug by the use of DWTI's original technology (The Drug Western method). Simultaneously DWTI will accelerate the licensing activity to pharmaceutical companies.

end